|
Rational Design and Clinical Development of Shepherdin: A Novel Anti-Cancer Agent
|
1R01CA118005-01A2
|
$340,386
|
$57,866
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Telomere Shortening and Stem Cell Maintenance
|
5K08CA118416-04
|
$140,010
|
$140,010
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
$116,889
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Resistance of CML Stem Cells to Imatinib (Gleevec)
|
5R01CA095684-06
|
$320,589
|
$320,589
|
BHATIA, RAVI
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Relapse after Allogeneci Hematopoietic Stem Cell Transplantation
|
ZIA BC 011239
|
$167,837
|
$151,053
|
Bishop, Michael
|
CCR (NCI)
|
|
Program on Molecular and Cellular Mechanisms of Tumorigenesis
|
5P01CA016519-34
|
$1,922,663
|
$192,266
|
BOEKE, Jef
|
JOHNS HOPKINS UNIVERSITY
|
|
In Vivo Analysis of Oncogenic Kras in Leukemogenesis
|
5K08CA103868-05
|
$127,170
|
$38,151
|
BRAUN, BENJAMIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S1
|
$89,606
|
$2,688
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
5P30CA016058-34
|
$3,956,712
|
$118,701
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Role of Redox Dependent Signaling in Leukemia
|
5R01CA115811-03
|
$292,600
|
$292,600
|
CHANDRA, JOYA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Signaling and targeting of FGFR1 fusions in 8p11 myeloproliferative syndrome
|
5R01CA120272-04
|
$263,700
|
$263,700
|
Chen, Jing
|
EMORY UNIVERSITY
|
|
NR4A Nuclear Receptor Function in Leukemia
|
3R01CA111411-04S1
|
$25,519
|
$25,519
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
|
NR4A Nuclear Receptor Function in Leukemia
|
5R01CA111411-04
|
$258,529
|
$258,529
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-08
|
$286,425
|
$286,425
|
COWELL, JOHN
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
Mechanisms of Leukemogenesis in Down Syndrome
|
5R01CA101774-07
|
$305,363
|
$152,682
|
CRISPINO, JOHN
|
NORTHWESTERN UNIVERSITY
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-11S1
|
$126,002
|
$20,160
|
DALTON, WILLIAM
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-11S2
|
$194,877
|
$31,180
|
Dalton, William
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
5P30CA076292-11
|
$3,021,607
|
$483,457
|
DALTON, WILLIAM
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Chronic Myelogenous Leukemia and Bcr-Abl Substrates
|
5R01CA065823-15
|
$310,291
|
$310,291
|
DRUKER, BRIAN
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
|
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
|
5R01CA129952-02
|
$287,173
|
$287,173
|
EPLING-BURNETTE, Pearlie K
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
HTS for Small Molecule Inhibitors of the RhoA Pathway
|
5F31CA113268-04
|
$14,921
|
$3,730
|
EVELYN, CHRIS
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
mTOR Signaling In Chronic Myelogenous Leukemia
|
5R01CA107041-05
|
$228,465
|
$228,465
|
FAN, HUNG
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S1
|
$94,753
|
$13,265
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S2
|
$107,415
|
$15,038
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S3
|
$100,000
|
$14,000
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-26
|
$2,342,475
|
$327,947
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Improving Biopsies using Magnetic Nanoparticles
|
5R44CA105742-04
|
$327,296
|
$65,459
|
FLYNN, EDWARD
|
SENIOR SCIENTIFIC
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-05S1
|
$1,079,832
|
$269,958
|
forman, stephen
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-20S2
|
$70,196
|
$1,404
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-20S3
|
$99,890
|
$1,998
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-20
|
$4,865,452
|
$97,309
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanism of combined 'epigenetic therapy' in myeloid malignancies
|
5R01CA125635-03
|
$486,728
|
$243,364
|
GORE, STEVEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
|
1R01CA132998-01A2
|
$323,700
|
$323,700
|
GRDINA, DAVID
|
UNIVERSITY OF CHICAGO
|
|
Role of Lipocalin 24p3 in Apoptosis and Leukemia
|
5R01CA115817-04
|
$252,065
|
$252,065
|
GREEN, MICHAEL
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Targeting Wnt/Ca2+ Pathway components and Bcr-Abl for the treatment of CML
|
1K01CA133182-01A2
|
$110,419
|
$110,419
|
GREGORY, MARK
|
UNIVERSITY OF COLORADO DENVER
|
|
Role of MN1-TEL and MN1 in Leukemogenesis
|
5R01CA072996-13
|
$333,189
|
$333,189
|
GROSVELD, GERARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Ex Vivo Alloanergization to Improve Immunity After Haploidentical Transplant
|
1R21CA137645-01A1
|
$370,550
|
$370,550
|
GUINAN, EVA
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer Center Support Grant (Comprehensive)
|
2P30CA015704-35
|
$10,977,925
|
$109,779
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S3
|
$249,999
|
$2,500
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S4
|
$85,601
|
$856
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S5
|
$100,000
|
$1,000
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Mechanisms of HOX Protein Mediated Transformation
|
5R01CA116570-04
|
$229,353
|
$229,353
|
Hess, Jay
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Functional Analysis of the Fanconi Pathway
|
5R01CA112775-12
|
$273,823
|
$68,456
|
HOATLIN, MAUREEN
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
|
MYELOPROLIFERATIVE DISORDERS RESEARCH CONSORTIUM
|
5P01CA108671-04
|
$4,738,076
|
$4,738,076
|
Hoffman, Ronald
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Negative Regulators of Myelopoiesis
|
5R01CA081168-10
|
$272,010
|
$68,003
|
HOFFMAN, BARBARA
|
TEMPLE UNIVERSITY
|
|
Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous
|
1R43CA139771-01
|
$149,616
|
$149,616
|
HOUSEY, GERARD
|
HOUSEY PHARMACEUTICAL RESEARCH LAB
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
3P50CA100632-07S1
|
$52,857
|
$26,957
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
Total relevant funding to Chronic Myeloproliferative Disorders for this search: $32,529,168
|